Emboline, Inc. Secures $20 Million for Product Launch of the Emboliner® System in Stroke Prevention
Emboline, Inc. Secures Funding for Revolutionary Stroke Prevention Technology
In a significant step for the medical technology sector, Emboline, Inc., based in Santa Cruz, California, has successfully secured $20 million in growth capital from Trinity Capital Inc., a prominent international alternative asset manager. This funding is crucial for advancing the commercialization of the Emboliner® Embolic Protection System, a device designed to mitigate the risk of stroke and other ischemic conditions during transcatheter aortic valve replacement (TAVR) procedures.
Emboline focuses on improving outcomes for patients undergoing structural heart procedures by reducing stroke and ischemic damage. The company recently completed enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial, which is a prospective randomized study evaluating the effectiveness of the Emboliner® device. This trial, numbered NCT05684146, is a pivotal step ahead of the anticipated commercial launch.
The Emboliner® Embolic Protection System works by providing full cerebral and systemic embolic protection through the capture and removal of debris that may be released during these heart procedures. This advancement in technology is particularly essential for enhancing procedural safety and efficacy. Furthermore, Emboline holds a comprehensive intellectual property portfolio related to aortic embolic protection, encompassing full-body embolic filtration and innovative aortic deflection techniques.
The results from the completed IDE clinical study will be prominently showcased during a Late-Breaking Clinical Trial session at the American College of Cardiology Annual Scientific Session in New Orleans, Louisiana, slated for March 29, 2026. This platform will provide the opportunity for healthcare professionals and industry stakeholders to evaluate the findings and implications of the clinical study.
Rob Lake, Senior Managing Director of Life Sciences at Trinity Capital, expressed confidence in Emboline’s technology: "Emboline's embolic filtering technology aims to empower interventional cardiologists with enhanced confidence when conducting complex procedures while concurrently reducing the risk of stroke and other complications. We are pleased to support Emboline during this transformative phase as they prepare to introduce their solution to the medical community worldwide.”
In his remarks, Scott Russell, President and CEO of Emboline, communicated the excitement surrounding the funding, stating: "We are eager to collaborate with Trinity Capital at this pivotal moment. The completion of our IDE clinical trial along with upcoming regulatory submissions positions us well for a commercial launch in both the United States and Europe within this year. Our objective is to equip physicians with a comprehensive embolic protection solution that minimizes the risk of stroke and ischemic injury during transcatheter procedures.”
With this strategic investment, Emboline is poised to enhance preparations for the commercial rollout of the Emboliner® Embolic Protection System, while continuing the development of innovative technologies aimed at reducing embolic risks during critical heart interventions.
About Trinity Capital Inc.
Trinity Capital Inc. (Nasdaq: TRIN) specializes in alternative asset management, focusing on delivering consistent returns for investors through access to private credit markets. The firm has a track record of sourcing and structuring investments in growth-oriented companies across several sectors, including Life Sciences, having deployed over $5.5 billion in more than 463 investments since its inception in 2008. Headquartered in Phoenix, Arizona, Trinity Capital stands as a long-term, trusted partner for companies seeking tailored debt solutions.
About Emboline
As a trailblazer in the medical technology field, Emboline, Inc. concentrates on developing innovative solutions to minimize embolic complications during cardiovascular procedures. Its flagship product, the Emboliner® Embolic Protection System, is engineered to safeguard vital organs by capturing and removing potentially harmful debris during cardiac interventions. Please note the Emboliner® device is still in the investigational stage and is not available for commercial sale yet.
For further details about Emboline and their groundbreaking work, visit emboline.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.